October 20, 2017
In patients with persistent or recurring Cushing’s disease after surgery, monthly pasireotide was safe and effective, leading to normal urinary free cortisol levels in about 40% of patients after 12 months, according to findings from a phase 3 clinical trial.
“Surgical resection of the causative pituitary adenoma is the first-line treatment of choice for most patients with Cushing’s disease, which leads to remission in greater than 75% of patients if done by an expert pituitary surgeon,” Andre Lacroix, MD, professor in the department of medicine at University of Montreal teaching hospital, and colleagues wrote in the study background. “However, surgery is not always successful, and disease recurrence can occur several years after initial remission, while some patients refuse or are not candidates for surgery. As a result, many patients require additional treatment options.”